Business Description
Toleranzia AB
ISIN : SE0007438577
Compare
Compare
Traded in other countries / regions
TOL.Sweden0EH.Germany IPO Date
2020-12-14Description
Toleranzia AB is a Swedish biotechnology Company. The company develops drugs that harness the power of the immune system to treat autoimmune orphan diseases The company's drug candidate, TOL2, is being developed for the treatment of the autoimmune neuromuscular disease myasthenia gravis, an orphan disease.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 11.47 | |||||
| Equity-to-Asset | 0.98 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.14 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 25.6 | |||||
| 3-Year EPS without NRI Growth Rate | 25 | |||||
| 3-Year FCF Growth Rate | -0.5 | |||||
| 3-Year Book Growth Rate | -14.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 47.95 | |||||
| 9-Day RSI | 52.1 | |||||
| 14-Day RSI | 52.95 | |||||
| 6-1 Month Momentum % | 6.19 | |||||
| 12-1 Month Momentum % | -61.29 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.83 | |||||
| Quick Ratio | 2.83 | |||||
| Cash Ratio | 2.52 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -53.6 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -4.53 | |||||
| ROA % | -4.34 | |||||
| ROIC % | -6.11 | |||||
| ROC (Joel Greenblatt) % | -5444.54 | |||||
| ROCE % | -4.43 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.79 | |||||
| Price-to-Tangible-Book | 16.59 | |||||
| EV-to-EBIT | -16.74 | |||||
| EV-to-Forward-EBIT | 0.99 | |||||
| EV-to-EBITDA | -16.82 | |||||
| EV-to-Forward-Revenue | 0.47 | |||||
| EV-to-FCF | -1.94 | |||||
| Price-to-Net-Current-Asset-Value | 15.35 | |||||
| Price-to-Net-Cash | 20.46 | |||||
| Earnings Yield (Greenblatt) % | -5.97 | |||||
| FCF Yield % | -44.07 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Toleranzia AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.004 | ||
| Beta | 1.96 | ||
| Volatility % | 158.31 | ||
| 14-Day RSI | 52.95 | ||
| 14-Day ATR (€) | 0.003432 | ||
| 20-Day SMA (€) | 0.02957 | ||
| 12-1 Month Momentum % | -61.29 | ||
| 52-Week Range (€) | 0.0108 - 0.0588 | ||
| Shares Outstanding (Mil) | 197.07 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Toleranzia AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Toleranzia AB Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Toleranzia AB Frequently Asked Questions
What is Toleranzia AB(FRA:0EH)'s stock price today?
The current price of FRA:0EH is €0.03. The 52 week high of FRA:0EH is €0.06 and 52 week low is €0.01.
When is next earnings date of Toleranzia AB(FRA:0EH)?
The next earnings date of Toleranzia AB(FRA:0EH) is 2024-08-23.
Does Toleranzia AB(FRA:0EH) pay dividends? If so, how much?
Toleranzia AB(FRA:0EH) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers